Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Rigel Pharmaceuticals Articles

AstraZeneca presents mixed data on fostamatinib in RA

13 December 2012

AstraZeneca gains rights to Rigel's asthma candidate R256

20 June 2012

Pfizer returns asthma drug candidate rights to Rigel Pharma; latter narrows losses

9 May 2011

AstraZeneca takes rheumatoid arthritis drug Fostamatinib into Ph III trials

30 September 2010

AstraZeneca/Rigel’s fostamatinib shows positive response in rheumatoid arthritis in Ph IIb study

22 September 2010

Showing 1-5 of 5 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Is the diabetes market facing a blockbuster-free future?
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Is the diabetes market facing a blockbuster-free future?
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS